PBLA — Panbela Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $1.17m
- $7.42m
Annual balance sheet for Panbela Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 2.45 | 9.02 | 11.9 | 1.28 | 2.58 |
| Net Total Receivables | 0.361 | 0.323 | 0.321 | 0.049 | 0.183 |
| Prepaid Expenses | |||||
| Total Current Assets | 3.09 | 9.76 | 12.3 | 1.78 | 3.06 |
| Other Long Term Assets | |||||
| Total Assets | 3.14 | 9.81 | 12.9 | 4.98 | 11.8 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Current Liabilities | 1.76 | 1.36 | 2.66 | 7.83 | 12.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 1.76 | 1.36 | 2.66 | 13 | 16.5 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 1.39 | 8.45 | 10.2 | -8.05 | -4.71 |
| Total Liabilities & Shareholders' Equity | 3.14 | 9.81 | 12.9 | 4.98 | 11.8 |
| Total Common Shares Outstanding |